Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Pseudomonas aeruginosa
Research reports on Pseudomonas aeruginosa from Brigham and Women's Hospital provide new insights
December 10th, 2008
According to a study from the United States, "In a murine model of acute fatal pneumonia, we previously showed that nasal immunization with a live-attenuated aroA deletant of Pseudomonas aeruginosa strain PAO1 elicited LPS serogroup-specific protection, indicating that opsonic Ab to the LPS O Ag was the most important immune effector. Because P. aeruginosa strain PA14 possesses additional virulence factors, we hypothesized that a live-attenuated vaccine based on PA14 might elicit a broader array of immune effectors. Thus, an aroA deletant of PA14, denoted PA14 Delta aroA, was constructed." "PA14 Delta aroA-immunized mice were protected against lethal pneumonia caused...
Source: Vaccine Weekly (2008-12-10)
|
